These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 653636)

  • 1. Antiserum against factor IX shortens the bovine thromboplastin coagulation time of human plasma.
    Orstavik KH; Laake K
    Thromb Res; 1978 Mar; 12(3):455-65. PubMed ID: 653636
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
    Orstavik KH
    Thromb Haemost; 1981 Dec; 46(4):684-6. PubMed ID: 7330818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor IX variants of hemophilia B. The effect of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules.
    Osterud B; Kasper CK; Prodanos C
    Thromb Res; 1979; 15(1-2):235-43. PubMed ID: 483278
    [No Abstract]   [Full Text] [Related]  

  • 4. Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor.
    Osterud B; Kasper CK; Lavine KK; Prodanos C; Rapaport SI
    Thromb Haemost; 1981 Feb; 45(1):55-9. PubMed ID: 7245126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the prolonged prothrombin time in haemophilia BM.
    Elödi S
    Thromb Diath Haemorrh; 1973 May; 29(2):247-52. PubMed ID: 4796945
    [No Abstract]   [Full Text] [Related]  

  • 6. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
    Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
    Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An investigation of three patients with Christmas disease due to an abnormal type of factor IX.
    Denson KW; Biggs R; Mannucci PM
    J Clin Pathol; 1968 Mar; 21(2):160-5. PubMed ID: 4972271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLASMA THROMBOPLASTIN COMPONENT (PTC) DEFICIENCY: A CASE REPORT.
    IDA M; TANAKA M
    Shonika Kiyo; 1963; 9():297-301. PubMed ID: 14112922
    [No Abstract]   [Full Text] [Related]  

  • 9. Consumption of serum factors and prothrombin during intravascular clotting in rabbits.
    Rapaport SI; Hjort PF; Patch MJ; Jeremic M
    Scand J Haematol; 1966; 3(1):59-75. PubMed ID: 5914457
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources.
    Lefkowitz JB; Monroe DM; Kasper CK; Roberts HR
    Am J Hematol; 1993 Jul; 43(3):177-82. PubMed ID: 8352232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The abnormal factor IX of hemophilia B+ variants.
    Bertina RM; Veltkamp JJ
    Thromb Haemost; 1978 Oct; 40(2):335-49. PubMed ID: 734633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic heterogeneity of hemophilia B.
    Brown PE; Hougie C; Roberts HR
    N Engl J Med; 1970 Jul; 283(2):61-4. PubMed ID: 5420360
    [No Abstract]   [Full Text] [Related]  

  • 13. Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
    Bertina RM; van der Linden IK
    Thromb Haemost; 1982 Apr; 47(2):136-40. PubMed ID: 7101232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The levels of factors II, VII, IX and X by antibody neutralization techniques in the plasma of patients receiving phenindione therapy.
    Denson KW
    Br J Haematol; 1971 Jun; 20(6):643-8. PubMed ID: 5089955
    [No Abstract]   [Full Text] [Related]  

  • 15. The separation of clotting factors II (prothrombin) and IX (plasma thromboplastin component) by isoelectric focusing.
    Pechet L; Smith JA
    Biochim Biophys Acta; 1970 Mar; 200(3):475-85. PubMed ID: 4985341
    [No Abstract]   [Full Text] [Related]  

  • 16. THROMBOPLASTIC ACTIVITY OF HUMAN SALIVA IN PATIENTS UNDER PROLONGED ANTICOAGULATION THERAPY.
    DOKU HC; TAYLOR RG; SISE HS; BECKER R
    J Dent Res; 1964; 43():323-30. PubMed ID: 14159035
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of activated factor X in the control of bovine coagulation factor VII.
    Morrison-Silverberg SA; Jesty J
    J Biol Chem; 1981 Feb; 256(4):1625-30. PubMed ID: 7462215
    [No Abstract]   [Full Text] [Related]  

  • 18. [Recent advances in hemophilia research].
    Ito S
    Rinsho Ketsueki; 1976 Jun; 17(6):580-9. PubMed ID: 787578
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hemophilia BM (abnormal factor IX in coagulation disorder) (author's transl)].
    Girolami A; Cella G; Patrassi G
    Haematologica; 1974 Mar; 59(1):91-108. PubMed ID: 4212668
    [No Abstract]   [Full Text] [Related]  

  • 20. Factor IX antigen by radioimmunoassay in heterozygotes for hemophilia B.
    Thompson AR
    Thromb Res; 1977 Aug; 11(2):193-203. PubMed ID: 905971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.